Figure_5.tif (967.61 kB)
Treatment of DIO mice with either FGF19 or FGF21 improves metabolic dysfunction.
figure
posted on 2013-02-20, 04:30 authored by Andrew C. Adams, Tamer Coskun, Armando R. Irizarry Rovira, Michael A. Schneider, David W. Raches, Radmila Micanovic, Holly A. Bina, James D. Dunbar, Alexei KharitonenkovAdministration of recombinant FGF19 or FGF21 led to a reduction in body mass in a dose dependent fashion (A). Both FGF19 and FGF21 therapy led to a trend towards increased food intake, however, these differences were not significant (B). Treatment with FGF19 or FGF21 significantly reduced adiposity at both doses tested again in a dose dependant manner (C), All FGF treatments caused a significant reduction in serum glucose in DIO animals, furthermore, the reduction in glucose observed with the two proteins was strikingly similar (D).
